You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

August 28, 2014

Good Manufacturing Practices in Thailand

Informed Counsel

In Thailand, Good Manufacturing Practices (GMP) were first implemented in 1979 for local pharmaceutical manufacturers under the Drug Act 1967 (B.E. 2510). In 1984, the Thai Food and Drug Administration (FDA) campaigned seriously for the pharmaceutical industry, and ultimately managed to update pharmaceutical standards, with the first Guidelines to Good Manufacturing Practices being issued in 1987. Also, as a way to standardize pharmaceutical factories, the Thai FDA began to officially grant GMP Certificates in 1989. 

By 2001, Thailand had adopted GMP Guidelines based on internationally recognized World Health Organization (WHO) standards, and in the same year, the Thai FDA applied the new guidelines to all local manufacturers and overseas manufacturers that intended to export drugs into Thailand.

GMP Accreditation

As an ASEAN member, Thailand has implemented ASEAN GMP. In order to comply with the ASEAN Sectorial Mutual Recognition Arrangement (MRA), which was signed on April 10, 2009, Thailand must standardize its GMP guidelines to be in line with those of other ASEAN countries. In 2011, the Thai FDA issued GMP regulations and launched GMP Guidelines that complied with ASEAN GMP standards and the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S)—this provided guidance to local manufacturers and raised overall standards.

In order to maintain the same GMP standards for both local and overseas manufacturers, the Thai FDA launched the Notification of GMP Accreditation of Overseas Manufacturers on October 1, 2012. Under this Notification, overseas pharmaceutical manufacturers which had never before been recorded in the Drug Product Registry of Thailand needed to be accredited by the Thai FDA before Marketing Authorization (MA) could be obtained. Pharmaceutical import companies must also submit an application for GMP accreditation before or at the same time as drug registration.

Required Documents

The documents to be submitted to the Thai FDA for GMP accreditation are separated into two schemes, Non-PIC/S members and PIC/S members, based on the overseas manufacturer’s country. If the overseas manufacturer is from a country that is a PIC/S member, the documents for GMP accreditation will be the PIC/S member checklist. The amount of documents for a PIC/S member to submit is less than that for a Non-PIC/S member. The required documents include:

  1. A Plant Master File for PIC/S or Non-PIC/S members or Certified/Audited by PIC/S, complying with the requirements stated in the Notification of the Ministry of Public Health Re: Good Manufacturing Practices (GMP) and Requirements for Manufacturing of Modern Drugs in accordance with the Drug Act 2012 (B.E. 2555).
  2. The production details of the imported product, including details about the place and manufacturing area, production equipment involved in the manufacturing of each category of imported product, plant layout, and a flowchart and other relevant information indicating all manufacturing processes, including the premises.
  3. The latest GMP inspection report, issued by the authorized government agency of the country of origin or the International Certificate Organization (if applicable).
  4. A current Certificate of GMP, issued by the authorized government agency of the country of origin.

Under the four topics above, there are more than 100 documents to be submitted for PIC/S members and more than 200 documents to be submitted for Non-PIC/S members to the Thai FDA for GMP accreditation. All documents are reviewed by an FDA team of experts. Afterwards, all questions, requests, or suggestions will be sent to the applicant to answer and/or submit additional documents. A slide or video presentation of the manufacturer needs to be prepared to explain the manufacturing process, such as important zones of production, flow of production, etc.

The applicant is required to arrange for the translation of certain information which needs to be in Thai and submit it together with the English version. A company representative may be requested to meet with the subcommittee to explain and answer the expert team’s questions. A Corrective Action and Preventative Action (CAPA) proposal may need to be presented to the subcommittee for evaluation. In complex cases, an inspection at the site of manufacturing may be required by the Thai FDA.  

If manufacturing practices are considered to be GMP compliant and the CAPA proposal meets requirements, the Thai FDA will issue a GMP Certificate to an overseas manufacturer for the purpose of product registration. The same GMP Certificate may be used for other product registration applications if they have the same scope/type of manufacturing during the validity of the GMP Certificate, which is normally three years after the date of issuance. The GMP Certificate of an overseas manufacturer must therefore be renewed every three years.

Since its implementation in October 2012, only 10 manufacturers from PIC/S member countries have received GMP accreditation. Meanwhile, manufacturers from Non-PIC/S member countries are still pending accreditation. Due to limited staff and expert teams in the Thai FDA, along with the requirement to submit a large number of documents for manufacturers from Non-PIC/S member countries, it is more difficult for a Non-PIC/S member to be granted a GMP Certificate than it is for a PIC/S member.

Overseas manufacturers are not required to pay for GMP accreditation at any stage of the application.

Renewal and Ongoing Audits

As the GMP Certificate issued for an overseas manufacturer has to be renewed every three years, it seems that the Thai FDA is trying to control/audit all manufacturers with products registered in Thailand. Meanwhile, local manufacturers normally have to renew their GMP Certificates every two years.

The GMP accreditation regulation of overseas manufacturers does not, however, affect manufacturers with products that were submitted for drug registration before October 1, 2012, because the manufacturer’s name and address are available in the Thai FDA database. It would be possible to have them audited if product registration renewal was required. Unfortunately, there is no requirement in Thailand for product registration renewal every five years, unlike other countries in ASEAN such as Singapore, Malaysia, etc. Therefore, these overseas manufacturers are still awaiting audit by the Thai FDA. For the time being, there are no measures to manage the audit of these manufacturers. To complete the GMP system in Thailand, the Thai FDA has the burden to eliminate the gap between new and old overseas manufacturers. This leaves many observers wondering how best to control products from overseas manufacturers that have never been audited by the Thai FDA.

Comparisons among ASEAN Countries

Thailand is not currently a PIC/S member, so in order to ascend to the accepted list of ASEAN MRA, Thailand must develop its pharmaceutical GMP system to be on par with other ASEAN countries. This will reduce pharmaceutical trade barriers before the ASEAN Economic Community (AEC) is implemented in December 2015.         

ASEAN countries have country-specific regulations that differ due to the laws and regulations of each country. As in Thailand, GMP accreditation in Singapore came into effect on April 1, 2004, and all overseas manufacturers registering medicinal products in Singapore after that date have to meet the PIC/S GMP standard. Malaysia, too, now requires the GMP accreditation of manufacturers outside Malaysia to be taken into consideration before products are registered. Malaysia adopted the PIC/S Guide to GMP for medicinal products in 2002.

In Malaysia and Singapore, old manufacturers with products that have already been registered, but have never been audited, will be audited and inspected when Marketing Authorization is renewed. If the manufacturer does not pass inspection, Marketing Authorization will not be granted. For Cambodia, Lao PDR, Myanmar, Philippines, and Indonesia, however, the GMP accreditation requirements for new overseas manufacturers are not as stringent as those seen in Malaysia and Singapore. The development of GMP accreditation in those countries will likely grow in the future to be on par with other ASEAN countries.

RELATED INSIGHTS​ 

August 10, 2026
On June 17, 2026, Indonesia’s National Agency of Drug and Food Control (BPOM) issued BPOM Regulation No. 10 of 2026 on Nutritional Information on Processed Food Labels. The new regulation, which revokes three previous nutrition labeling regulations, introduces several notable changes affecting food and beverage manufacturers, importers, and distributors. These changes range from updated nutrient reference values and serving-size requirements to the introduction of the Nutri-Level front-of-pack labeling system for certain beverage products. Businesses operating in Indonesia should carefully review these developments and assess their products’ compliance with the new requirements during the transition period. Implementation of the Nutri-Level Labeling System To implement the recently issued decree on Nutri-Level labeling, BPOM Regulation No. 10 of 2026 stipulates the requirements to implement the Nutri-Level labeling system on the front-of-pack. Under the new framework, ready-to-drink beverages, powdered beverages, and liquid or solid concentrates are required to display Nutri-Level labeling on the front label of their packaging. The Nutri-Level labeling system classifies products into color-coded levels A through D based on their sugar, sodium, and total fat content. The applicable Nutri-Level is determined based on the lowest level measured in the assessment of sugar, sodium, and total fat content. For products classified as level C or D, the Nutri-Level label must be accompanied by information on the relevant sugar, sodium, and total fat content per 100 ml of the ready-to-consume product. Products classified as level A or B may either display only the Nutri-Level designation or display the Nutri-Level together with the relevant nutritional information per 100 ml. Minimum Vitamin and Mineral Content Required for Declaration BPOM Regulation No. 10 of 2026 introduces a stricter threshold for the declaration of vitamins and minerals in the nutritional value information section (ING). Vitamins or minerals may only be declared if they are present at a
August 10, 2026
The drug registration process in Vietnam will be simplified, particularly for foreign applicants, following the recent issuance by Vietnam’s Ministry of Health (MOH) of a new circular that is expected to reduce administrative hurdles. Circular No. 32/2026/TT-BYT on the registration of drugs and medicinal ingredients (Circular 32) was issued on July 29, 2026, and will take effect on October 1, 2026, replacing Circular No. 12/2025/TT-BYT. Key provisions of the new circular are discussed below. Five-Year Data Exclusivity and Five-Month Public Disclosure Framework Circular 32 updates data protection guidelines by explicitly referencing Article 128 of the amended Intellectual Property Law, which sets out that new drugs supported by clinical trial data submitted for the first time will be granted a five-year data exclusivity period from the date of the initial marketing authorization (MA) approval. Subsequent applications that rely on the originator’s protected data will not be eligible for approval from the date of submission of the originator’s registration dossier until five years after the first MA is granted. Furthermore, in accordance with the new regulations, the regulatory authority must publicly disclose information on subsequent applications five months before the granting of MA, providing originator companies with an opportunity to exercise and enforce their intellectual property rights. Simplified Requirements for Foreign Legal Documents Circular 32 expands the circumstances under which legal documents issued by foreign authorities are exempt from consular legalization and authenticity verification requirements. Specifically, such documents may be exempt if the Drug Administration of Vietnam (DAV) is able to verify their authenticity directly through official electronic means, including written confirmation or email correspondence sent directly to the MOH by the competent foreign authority, or publicly accessible English-language databases maintained by recognized foreign regulatory authorities. In addition, the new circular permits the submission of electronic notarized copies of legal documents
July 24, 2026
As food innovation continues to accelerate, manufacturers are increasingly introducing ingredients derived from new sources, produced using novel technologies, or lacking a significant history of human consumption. While these innovations create new opportunities for the food industry, they also raise important questions regarding consumer safety. For this reason, many jurisdictions, including Thailand, the European Union, Australia and New Zealand, Canada, and Singapore, require a premarket safety assessment for novel food ingredients before they can be placed on the market. The objective of this assessment is to ensure that each ingredient is safe for its intended use and level of consumption, does not present toxicological, allergenic, microbiological, or nutritional concerns, and will not mislead consumers. Scientific authorities typically evaluate the ingredient’s identity, manufacturing process, composition, specifications, anticipated dietary exposure, toxicological information, nutritional impact, and history of use before determining whether it can be marketed. Against this background, the Thai Food and Drug Administration (FDA) recently took an important step toward improving regulatory transparency by publishing, for the first time, a consolidated public list of substances that have successfully completed the Thai FDA’s safety assessment process, including substances determined to be novel foods and those determined not to fall within the novel food category. The list identifies the approved substances, the corresponding manufacturers or importers, approval dates, and the approved conditions of use. Although the publication does not change the existing legal framework governing novel food approvals, it provides businesses with greater visibility into the Thai FDA’s regulatory precedents and the types of substances that have previously been accepted through the safety assessment process. The full announcement is available on the Thai FDA’s website. As the list is now publicly available, it also provides useful insight into the types of substances that have successfully completed the Thai FDA’s safety assessment process.
July 24, 2026
For businesses in Thailand’s regulated industries, the problem of “too many licenses” is one of the most familiar hurdles to getting a product to market. Take a simple example: importing the materials necessary to sell teriyaki chicken skewers. To legally do this, a business may need approvals from several different agencies—separate permits for the chicken (Department of Livestock Development), the dipping sauce (Thai FDA), the wooden skewers (Department of Forestry), and other ingredients, each under a different authority. This kind of overlap is often cited to argue for a “regulatory guillotine”—a systematic review to cut outdated or duplicative rules that slow investment and business activity. The Facilitation of Licensing and Public Service Consideration Act B.E. 2569 (2026) (Licensing Facilitation Act 2026) is Thailand’s most significant response yet to that concern. This article looks at the Facilitation Act 2026 through a life sciences and regulatory affairs lens—what it may mean for the manufacturers, importers, and distributors of food, drugs, medical devices, cosmetics, and similar products who routinely deal with several regulators to bring a single product to market. The Super License: One Approval Standing in for Many The reform with the clearest potential for regulated-product businesses is the law’s “super license” mechanism, referred to as a “main license” in the statute. Once a business obtains the main license for a regulated activity, it is automatically deemed to hold all related sublicenses issued by other agencies for that same activity, provided the activity has been designated as eligible in the Government Gazette. The Licensing Facilitation Act 2026 also creates a central application center, allowing applicants to submit a single application and pay all relevant fees at one point of contact, with the center routing the application to each agency through a shared information system. The potential benefits of this for businesses